

Bod is a cannabis centric healthcare company. With a global focus and a mission to innovate and transform the way we live and enjoy life. Delivering premium, proven and trusted products for both the consumer markets and medical markets. Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications with education, research and knowledge.

CAPITAL STRUCTURE

ASX code **BDA**
 Shares on issue 84.2m
 Market Capitalisation ~\$39.5m

BOARD & MANAGEMENT

Mr Mark Masterson
 Non-Executive Chairman

Ms Jo Patterson
 Chief Executive Officer

Mr Akash Bedi
 Non-Executive Director

Mr George Livery
 Non-Executive Director

Mr Patrice Malard
 Non-Executive Director

Mr Simon O'Loughlin
 Non-Executive Director

Mr Stephen Thompson
 Alternate Director

Mr Stephen Kelly
 Company Secretary

CONTACT

Level 1, 377 New South Head Rd
 Double Bay, NSW 2028

T +612 9199 5018
 E info@bodaustralia.com.au

Bod enters research collaboration with UniSA for medicinal cannabis products

- **Bod to collaborate with the University of South Australia to conduct additional research on MediCabilis™ products**
- **Collaboration will expedite future product indications which have the potential to contribute to sales and an increase in prescription volumes**
- **Research will provide clinicians a better understanding of MediCabilis™ Bod's medicinal cannabis products – supports education and builds confidence**
- **Research will provide invaluable information for clinical practice and will lay a strong foundation for future trial initiatives**
- **Supports Bod's commitment to cost effective research and defrays capital expenditure against future revenue**
- **Results expected by March 2020 with commercialisation initiatives to follow**

Sydney, Australia - 12 December 2019: Medicinal cannabis healthcare products company, Bod Australia Limited ("Bod", the "Company") (ASX: BDA), is pleased to advise that it has entered into a research collaboration with the University of South Australia ("UniSA"), under which both parties will further research Bod's MediCabilis™ Cannabis product.

As part of the collaboration, Bod and UniSA will study MediCabilis™ and its effects on patients. The research will assist in ongoing product development initiatives, as well as provide valuable information for clinical practice and future research. Efforts from the collaboration may assist in Bod gaining potential registered indications for MediCabilis™.

The collaboration will be undertaken with researchers from UniSA's School of Pharmacy and Medical Sciences. This is a nationally renowned department bringing together internationally recognised health researchers in the quality use of medicines, drug development and pharmaceutical science.

The results from the collaboration will lay a strong foundation for additional research initiatives with Bod's exclusive extract, leaving Bod well positioned to exploit potential additional revenue streams. Further, the Company is confident that data from the collaboration will assist clinicians and approved prescribers in gaining a better understanding of MediCabilis™, allowing greater acceptance amongst physicians and growth in prescription volumes.

The initiative also supports a cost effective approach towards medical research and product development, allowing Bod to retain a strong cash balance and financial flexibility.

UniSA Senior Research Fellow Dr Stephanie Reuter Lange said: "This research will provide valuable information to facilitate further product development and guide clinical utility. This collaboration represents a high-quality approach that will enhance and build on the high-calibre research previously conducted by Bod."

CEO Jo Patterson said: "Entering into a research collaboration with such a high calibre organisation to progress product development and clinical utility initiatives surrounding our MediCabilis™ product provides tremendous validation of our approach to date and ongoing commitment to R&D, building IP and generating revenue

“This collaboration will not only provide Bod with a strong foundation for future research and trial initiatives, but also allows for a cost effective approach to R&D which simultaneously bolsters confidence and visibility for our product with approved prescribers.

“We look forward to working with UniSA and updating the market on outcomes as they develop.”

- ENDS -

ABOUT BOD AUSTRALIA

Bod Australia Limited (ASX:BDA) Bod is a cannabis centric healthcare company.

With a global focus and a mission to innovate and transform the way we live and enjoy life.

Delivering premium, proven and trusted products for both the consumer markets and medical markets.

Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications through education, research and trials.

This announcement was authorised for release by the Board of Directors of Bod Australia Limited.

For more information please contact:

Jo Patterson
Chief Executive Officer
info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538